94 related articles for article (PubMed ID: 12086799)
1. Is the NICE process flawed?
Cassidy J; Bridgewater J; Mainwaring P; Steward W; Wasan H
Lancet; 2002 Jun; 359(9323):2119-20. PubMed ID: 12086799
[No Abstract] [Full Text] [Related]
2. Why hasn't the National Institute been 'NICE' to patients with colorectal cancer? National Institute of Clinical Excellence.
Saunders MP; Valle JW
Br J Cancer; 2002 Jun; 86(11):1667-9. PubMed ID: 12087447
[No Abstract] [Full Text] [Related]
3. Welcome clinical leadership at NICE.
Lancet; 2008 Aug; 372(9639):601. PubMed ID: 18722845
[No Abstract] [Full Text] [Related]
4. Imatinib for chronic myeloid leukaemia: a NICE mess.
Barbour V
Lancet; 2001 Nov; 358(9292):1478. PubMed ID: 11705557
[No Abstract] [Full Text] [Related]
5. Experts condemn "flawed" NICE process over its rejection of prostate cancer drug.
O'Dowd A
BMJ; 2014 Aug; 349():g5224. PubMed ID: 25139515
[No Abstract] [Full Text] [Related]
6. [Off-label prescriptions. Drug use outside of established guidelines and treatment standard].
Weissbach L; Boedefeld EA
Urologe A; 2003 Mar; 42(3):428-32. PubMed ID: 12723544
[No Abstract] [Full Text] [Related]
7. New drug approved for colorectal cancer.
FDA Consum; 2002; 36(5):2. PubMed ID: 12412532
[No Abstract] [Full Text] [Related]
8. Molecule of the month. Vorinostat.
Drug News Perspect; 2006; 19(6):352. PubMed ID: 16971971
[No Abstract] [Full Text] [Related]
9. FDA approves regorafenib (Stivarga) for metastatic colorectal cancer.
Oncology (Williston Park); 2012 Oct; 26(10):896. PubMed ID: 23175993
[No Abstract] [Full Text] [Related]
10. The value and effectiveness of angiogenesis inhibitors for colorectal cancer.
Venook AP
Clin Adv Hematol Oncol; 2015 Sep; 13(9):561-3. PubMed ID: 26452184
[No Abstract] [Full Text] [Related]
11. Reporting time-to-event endpoints and response rates in 4 decades of randomized controlled trials in advanced colorectal cancer.
Arkenau HT; Nordman I; Dobbins T; Ward R
Cancer; 2011 Feb; 117(4):832-40. PubMed ID: 20886631
[TBL] [Abstract][Full Text] [Related]
12. FDA approves aflibercept (Zaltrap) for metastatic colorectal cancer.
Oncology (Williston Park); 2012 Sep; 26(9):842, 873. PubMed ID: 23061342
[No Abstract] [Full Text] [Related]
13. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway.
Kopetz S; Overman M; Chang DZ; Glover KY; Shureiqi I; Wolff RA; Abbruzzese JL; Eng C
J Clin Oncol; 2008 Apr; 26(12):2000-5. PubMed ID: 18421052
[TBL] [Abstract][Full Text] [Related]
14. New possibilities in chemotherapy for colorectal cancer.
Bekradda M; Cvitkovic E
Ann Oncol; 1999; 10 Suppl 6():105-11. PubMed ID: 10676561
[No Abstract] [Full Text] [Related]
15. Oxaliplatin.
Graham J; Mushin M; Kirkpatrick P
Nat Rev Drug Discov; 2004 Jan; 3(1):11-2. PubMed ID: 14756144
[No Abstract] [Full Text] [Related]
16. Comparative effectiveness research: NICE for the NHS, but false starts for the US.
Lyles A
Clin Ther; 2008 Sep; 30(9):1702-3. PubMed ID: 18840376
[No Abstract] [Full Text] [Related]
17. New drugs for colorectal cancer based on Japanese experience.
Ohtsu A
J Gastroenterol; 2000; 35 Suppl 12():132. PubMed ID: 10779235
[No Abstract] [Full Text] [Related]
18. [Colorectal carcinoma--approval of eloxatine in adjuvant therapy--better chances for recovery].
Krankenpfl J; 2004; 42(7-10):234. PubMed ID: 15675396
[No Abstract] [Full Text] [Related]
19. [Multikinase inhibitor regorafenib offers an efficient therapeutic alternative].
Rev Med Suisse; 2014 May; 10(431):1108. PubMed ID: 24941678
[No Abstract] [Full Text] [Related]
20. When Life Expectancy is Not Short Enough: A Perspective on the National Institute for Health and Care Excellence (NICE) Preliminary Guidance for Dinutuximab.
Adamson PC; Park JR; Pearson AD
Pediatr Blood Cancer; 2016 Jun; 63(6):962-3. PubMed ID: 26740172
[No Abstract] [Full Text] [Related]
[Next] [New Search]
